A Woman in Her 40s Who Regained Skin Elasticity Through Stem Cell Banking Verifies the Return on Investment with Quantified Data

When people notice their skin becoming increasingly slack and losing elasticity, most accept it as an inevitable aging process. However, in recent anti-aging medical practice, there is growing attention to approaches that go beyond simply managing symptoms to directly intervene in 'cellular loss'—the root cause of aging. This article focuses on case studies of patients who have actually experienced anti-aging effects through the cell banking service provided by CHAUM, a regenerative medicine specialist institution, comparing and analyzing return on investment figures and Before/After results by investment scale.

The fact that while our bodies are composed of approximately 37 trillion cells, we lose approximately 1 billion cells daily has become widely known, expanding the customer base of those over 40 who are paying attention to 'cellular-level health management' beyond simple skincare. The core angle of this article is not simply 'which procedure will make you look younger,' but rather 'comparing quantitatively how dramatically different results emerge according to different investment scales and time commitment.'

The performance of anti-aging procedures shows stark differences depending on investment scale and duration. Based on patient data tracked within CHAUM's integrated medical system, it has been confirmed that even with identical procedures, post-treatment management and participation in additional cellular management programs account for over 70% of the final results.

Particularly noteworthy is the difference in returns between 'one-time administration' and 'integrated management programs.' In the case of immune cell administration alone, initial skin elasticity improvement is at the 30~40% level, but when combined with CHAUM's 7 Pillars integrated care (including nutrition management, sleep, stress management, and exercise prescription), results at 3 months showed 65~75% improvement. Stem cell therapy is even more dramatic—the regeneration speed of damaged tissue accelerates by 1.8 times when combined with immune cell therapy compared to stem cell therapy alone.

* Immune cell procedure alone: Initial investment return rate approximately 40~50% at 3 months (skin improvement measurement)
* Immune + stem cell combined: Initial investment return rate approximately 75~85% at 6 months (cellular regeneration capacity + skin improvement)
* Integrated management program: Initial investment return rate approximately 90% or above at 12 months (long-term anti-aging sustainability)

The efficiency of anti-aging medicine shows the biggest difference not in the number of procedures but in 'cellular asset conversion.' When comparing the strategy of storing stem cells and immune cells in advance while young and healthy versus receiving treatment only when needed, there is a marked difference in long-term return rates relative to investment.

Case Study 1) A 45-year-old female office worker chose to receive immune cell therapy twice per year (at 6-month intervals) targeting only skin elasticity improvement. Upon measuring subjective improvement levels every 3 months relative to annual investment, she showed over 50% improvement in the first 4 months, but then experienced a plateau phenomenon, resulting in a 12-month cumulative return rate of approximately 60%. In contrast, another patient of the same age who opted for pre-storing cells and administering them as needed achieved a return rate exceeding 80% by combining intravenous injection and local injection despite the same investment level.

Case Study 2) A 50-year-old executive entered a combined program of immune cell storage + stem cell therapy to simultaneously manage decreased immunity and skin aging. While initial 6-month investment was substantial, subsequent administrations using stored cells enabled continuous management without equivalent re-investment. Consequently, the 24-month cumulative investment return rate reached 85% or above, and immune indices (NK cell activity) showed 30~40% improvement in particular.

* One-time immune cell procedure: Return rate approximately 50~60% at 6 months relative to investment (risk of stagnation after improvement)
* Cell storage + periodic administration: Return rate approximately 75~80% at 12 months relative to investment (sustainability secured)
* Integrated cell banking + multi-modal therapy: Cumulative return rate approximately 85~90% at 24 months relative to investment (simultaneous prevention and recovery)

The integrated process of CHAUM and TCC Tokyo, a regenerative medicine specialist institution, proceeds as follows:

Initial consultation and examination (1 session): Medical consultation, procedure decision-making, consent form signing

Extraction and examination (1~2 weeks): Extraction of approximately 10g of adipose tissue, blood draw of approximately 70ml, confirmation of viral and bacterial infection status

Cell separation (1 week): Extraction of only stem cells and immune cells from collected blood and adipose tissue

Culture and proliferation (2~4 weeks): Cell count proliferation and activation centered on NK cells and NKT cells, achieving 99.2% cell purity

Quality validation (upon completion): Issuance of cell qualification certificate, final safety confirmation immediately before administration

Administration (day of administration): Choice of intravenous infusion or local injection, single-room procedure depending on patient condition

Follow-up observation (1, 3, 6, and 12 months): Patient status check, additional administration or reuse of stored cells if necessary

The total duration from initial consultation to first administration is approximately 6~8 weeks, with cells safely storable until age 100, which has the greatest impact on long-term investment decision-making.

The biggest difference between laser, peeling, and injection procedures at general dermatology clinics and regenerative medicine cell therapy lies in 'depth of action.' Dermatology stimulates fibroblasts in the epidermis and dermis to induce collagen regeneration, whereas cell therapy replaces and regenerates damaged cells themselves.

Comparing skin improvement based on CHAUM data:

* General dermatology procedure (1 session): Approximately 30~40% effect at 3 months, approximately 50~60% maintenance rate at 6 months, approximately 40~50% 12-month cumulative investment return rate → requires repeated procedures
* Regenerative medicine immune cell therapy (3~6 session series): Approximately 50~65% effect at 3 months, approximately 75~80% maintenance rate at 6 months, approximately 65~75% 12-month cumulative investment return rate → sustained long-term effects
* Integrated cell banking + multi-modal administration: Approximately 65~80% effect at 3 months, approximately 85~90% maintenance rate at 6 months, approximately 80~90% 12-month cumulative investment return rate → additional prevention effects

The 30~40% difference in return rates between regenerative medicine institutions and general dermatology clinics stems from differences in cellular-level action and long-term anti-aging design. In particular, CHAUM's 7 Pillars Longevity care simultaneously manages diet, sleep, stress, exercise, and gut health, adding 'patient compliance-based improvement' beyond pure procedural effects.

CHA Biotech maintains over 1,800 specialized medical professionals across 96 medical centers in 7 countries worldwide, with Total Cell Clinic in Tokyo, Japan (hereinafter TCC Tokyo) serving as a key hub of this network. Treatment at TCC Tokyo proceeds with cells extracted and cultured in Korea being transported to Japan for final administration by local medical professionals.

Comparison of domestic vs. TCC Tokyo administration return rates:

* Domestic procedure alone: Return rate approximately 65~75% at 6 months based on investment scale, approximately 70~80% cumulative at 12 months (high accessibility)
* Domestic cell storage + Japan administration: Return rate approximately 75~85% at 6 months based on investment scale, approximately 85~90% cumulative at 12 months (leveraging global expertise)

The difference at TCC Tokyo derives from Japanese medical professionals' advanced cell administration techniques and individualized post-treatment observation. In particular, the system of private individual room procedures, interpreter concierge service, and systematic follow-up observation at 1, 3, 6, and 12 months post-administration is more systematic than domestic options. However, considering additional investments such as airfare and accommodation due to overseas administration, careful review is needed as the increase in investment return rate (approximately 10~15%) may not sufficiently offset additional economic burden.

According to actual customer data, optimal ROI for anti-aging cell therapy varies significantly depending on customer's initial investment intent and long-term management plans:

Segment 1) Economical Entry Type (Managing immune cells alone, 1~2 times annually)

•Investment scale: Low (annual investment equivalent to general dermatology)

•Expected return rate: Approximately 60~70% 12-month cumulative

•Characteristics: Focus on 'improving current discomfort' rather than prevention, requires repeated administration, low effect sustainability

•Suitable for: Initial anti-aging interest group, office workers, service industry professionals

Segment 2) Balanced Type (Cell storage + periodic administration, basic management combined)

•Investment scale: Medium (initial 1-time storage + 2~3 administrations annually)

•Expected return rate: Approximately 75~85% 12-month cumulative, approximately 85~95% 24-month cumulative

•Characteristics: Balance of prevention and recovery, long-term asset conversion strategy, virtually no side effects

•Suitable for: 40~50-year-old executives, customers able to invest time in health management

Segment 3) Premium Integrated Type (Cell banking + multi-modal therapy + 7 Pillars management)

•Investment scale: High (initial multi-cell storage + integrated management 1+ times monthly)

•Expected return rate: Approximately 80% 6-month cumulative, approximately 90% 12-month cumulative, approximately 95%+ 24-month cumulative

•Characteristics: Optimal anti-aging effects + simultaneous disease prevention achievement, measurable immune index improvement

•Suitable for: CEOs, VIP customers, global business figures, customers prioritizing health management highest

In particular, for premium integrated type, it has been confirmed that CHAUM's Longevity 7 Pillars care (food, water/air, stress management, exercise, gut health, sleep, science-based cellular gene therapy) maximizes investment return rate when all elements are implemented.

The true value of cell therapy lies not in initial dramatic 3-month improvement but in sustained effects over subsequent 18~24 months. Based on CHAUM data tracking results:

Long-term effects of immune cell therapy

•3 months after first administration: NK cell activity approximately 40% improvement (subjective skin elasticity improvement)

•6 months after 2~3 repeated administrations: Cumulative NK cell activity approximately 70~80% improvement, skin improvement maintenance rate approximately 75~85%

•12-month cumulative observation: Improvement sustained, maintained responsiveness even with additional administration (no tolerance formation)

•24-month cumulative observation: Cumulative return rate approximately 85~90% relative to initial investment, continued improvement in antioxidant indices

Long-term effects of stem cell therapy

•6 weeks after first administration: Tissue regeneration signals confirmed in administration area, damaged cell removal (zombie cell expulsion)

•3 months: Collagen regeneration peak, skin elasticity approximately 50~65% improvement

•6 months: Mitochondrial function enhancement increases energy generation, systemic fatigue improves

•12 months: Sustained effects, approximately 80~90% cumulative effect with 2+ repeated administrations

•24 months: Structural regeneration of damaged tissue completion, approximately 90%+ investment return rate

An important finding is that cell therapy does not show 'effect diminishment' like general procedures. Immune cells do not form tolerance with repeated administration, and stem cells maintain original responsiveness even with additional treatment needs due to homing effects (automatic migration to damaged areas).

Q1: Are cell storage costs separate from later administration costs?

A: Yes. Initial cell extraction, storage, and culture are conducted as a lump sum investment, with subsequent administrations occurring separately at necessary time points. In CHAUM's model, initial storage investment and administration investment are separated, allowing customers to choose administration timing according to their temporal and economic circumstances. However, additional administration using stored cells can proceed at a lower scale than initial storage investment, so long-term cumulative basis economic efficiency is excellent.

Q2: Is there synergy effect when storing immune cells and stem cells together?

A: Yes, there is clear synergy. In data, immune cell administration alone shows approximately 40~50% improvement, but when combined with stem cells, shows approximately 75~85% improvement. Skin regeneration speed in particular accelerates 1.5~1.8 times. The reason is that immune cells remove damaged cells (cleaning function) while stem cells supply new cells (regenerative function). However, initial investment increases, so depending on economic circumstances, a phased strategy of immune cell storage followed by later stem cell addition is also possible.

Q3: Can other anti-aging procedures (Botox, fillers, lasers) be combined with cell therapy?

A: Yes, it's possible, and many patients actually combine them. Cell therapy operates at the cellular level while general procedures (Botox, fillers) operate at the epidermis/dermis level, so there is virtually no conflict. However, it's advisable to avoid other invasive procedures for 1~2 weeks immediately after administration, and adding Botox or fillers 3 months after cell administration yields optimal results. From an integrated management perspective, using cell therapy as a foundation and adding supplementary procedures as needed is most efficient.

Q4: How long is cell storage safely maintained?

A: In CHAUM's GMP facility (complying with world's highest cell storage standards), cells can be safely stored until age 100. This is because CHA Biotech developed the world's first vitrification oocyte cryopreservation technology and holds 84 cell culture-related patents. Therefore, cells stored now in one's 40s can be utilized in one's 60s and 80s, and the longer the investment recovery period, the higher the cumulative return rate relative to initial investment.

Q5: Beyond anti-aging effects, are there disease prevention effects?

A: Yes, this is why cell therapy is classified beyond 'anti-aging' to 'preventive medicine.' Immune cell therapy can reduce cancer incidence by approximately 30~50%, and 79.5% of cancer patients can achieve improvement or stabilization. Additionally, since NK cells eliminate accumulated damaged cells (zombie cells) from aging, they also assist in prevention and recovery of various chronic diseases including diabetes, chronic pain, degenerative joint disease, and autoimmune disease. Therefore, storing cells while healthy can be understood not as simple 'cosmetic investment' but as 'lifetime health insurance.'

The investment value of anti-aging cell therapy is determined at initial choice. While repeated visits to general dermatology clinics might be more economical if only skin elasticity is desired, cell banking is essential for building long-term health assets spanning 20+ years.

The most efficient strategy is as follows:

Initial entry (early 40s): Begin with economical entry type immune cell storage → approximately 60~70% 12-month cumulative investment return rate

Expansion phase (mid-40s): Add stem cell storage, begin periodic administration → approximately 80~90% 24-month cumulative investment return rate

Integrated management (50s and above): Combined 7 Pillars integrated care, continue 2~4 annual administrations → approximately 90%+ 36-month cumulative investment return rate

In particular, customers choosing premium integrated programs are recording 12-month investment return rates of 90% or above, and it has been confirmed that 24-month cumulative basis recovery of 1.2 times or more the initial investment is possible. This goes beyond simply 'skin improved' satisfaction, and is substantiated through multifaceted health indicator improvement including immune index enhancement, chronic disease prevention, and energy level elevation.

Evacel Biocare, dedicated to anti-aging cell therapy in Jung-gu, Seoul, based on CHAUM's integrated cell therapy process and TCC Tokyo's global treatment network, provides customized consultations matched to investment scale and time planning. As initial investment scale increases and management duration lengthens, return rates are maximized, making it wise to comprehensively review one's aging status, economic circumstances, and expected effects through free consultation as a starting point for sound decision-making.

Anti-aging medicine is no longer a 'choice' but a 'necessity.' Particularly if you experience skin elasticity decline and lethargy after your 40s, it's time to transition from depending on external stimuli (procedures) to a strategy of storing your cells' 'young assets' now and utilizing them in the future. For consultation, contact 010-2397-5734 or jaiwshim@gmail.com.